FierceBiotech· @FierceBiotech · X·· 12 天前AI 评分50
AI 导读
Rezera(原 NodThera)计划通过 IPO 募资 1.81 亿美元,用于推进其主打 NLRP3 抑制剂明年进入外周动脉疾病的 3 期试验。
正文
Rezera, formerly known as NodThera, is targeting $181 million in IPO proceeds to advance its lead NLRP3 inhibitor into a phase 3 trial for peripheral artery disease next year. https://www.fiercebiotech.com/biotech/rezera-revs-181m-ipo-fund-phase-3-trial-nlrp3-inhibitor
来源:FierceBiotech · x.com